PEABODY, MA, August 12, 2021 /24-7PressRelease/ -- Dr. Tina Guanting Qiu has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Qiu obtained a medical degree (MD), with honors, from Nanchang University in China in 1992 before continuing her education with Doctorate of Clinical Ophthalmology with a PhD research project in stem cell therapy from National Sun Yat-sen University in Guangzhou in 2001. With the Keck School of Medicine at the University of Southern California from 2002 to 2006, she worked as a guest research physician and senior research fellow in ophthalmology. Furthermore, Dr. Qiu participated in a co-joint PhD thesis research on the retina at the Scheie Eye Institute at the University of Pennsylvania in Philadelphia in 2001.
From 2006 to 2008, Dr. Qiu flourished with GSK Pharmaceuticals in Pennsylvania as a principal investigator and cross-functional program leader for a retinal drug delivery innovation team, she was the scientific backbone to help GSK put ophthalmology on their portfolio map. She was hired by Inotek Pharma and Astellas Pharma twice, during which she made measurable social economic impact in pioneering the big data new frontier to advance retinal specialty care and glaucoma drug development. From 2012 to 2013, she made an impact in Massachusetts as a field medical consultant with Sucampo Pharmaceuticals, where she was the scientific backbone in supporting the company to obtain FDA approval of Rescula, a drug utilized in the treatment of glaucoma. She has served as Chief Medical Officer with BetaStem Therapeutics Inc and ProFarma, and an Ophthalmic-Clinical expert and Retinal Surgeon advising Sanofi Aventis, Regeneron and LambdaVision on cutting edge gene therapy and artificial retinal implant etc. Since 2016, Dr. Qiu has found success as founder and chief strategic and development clinician with Ophthalmic Therapeutic Innovation in Massachusetts, where she has developed a powerful strategic principle and intangible data know-how to address the most difficult problem in modern medicine development: 90% failure.
Most recently Dr. Qiu serves as Consulting Chief Scientific & Medical Officer for Lineage Cell Therapeutics on the world class human embryonic stem cell derived retinal pigment epithelium cell (hESC-RPE) transplant for the treatment of age-related macular degeneration (AMD). She is the inventor for a novel approach to reprogram adult human retinal cell for retinal repair, along with colleagues at Lineage Stem Cell Therapeutics, she contributed as co-inventor to the methods and use of hESC-RPE transplant for treating retinal diseases. She is the lead inventor for a novel angiogenesis model for AMD therapeutic development and pioneered in a minimally invasive subretinal delivery (SurModics RetinaJect) for gene & cell therapy, which has generated significant social economic impact in advancing the field clinical development with success, such as Luxturna, the first FDA approved human gene therapy for retinal disease. She has accrued many honors during her career, including the GSK Bronze Award for Outstanding Contributions for Research and Development of Ocular Drug Delivery Technology Innovation in 2007. She was also presented with a Translational Retinal Research Grant from National Eye Research Center in England in 2009, and a Best Paper Award from EC Ophthalmology in 2015. Her breakthrough research in retinal stem cell therapy was featuring at Scientific America in the USA, Bristol Evening Post and National Eye Research Center in England in 2009.
Dr. Qiu is an elected member of the American Academy of Ophthalmology. She has been further affiliated with the Chinese Ophthalmological Society, the Association for Research in Vision and Ophthalmology, Doheny Eye Institute at the University of Southern California and Gerson Lehrman Group. She attributes her success to discipline, perseverance, passion, integrity and intelligence. She was mentored by visionary and reknown retinal surgeon, Dr. Eugene de Juan Jr. and top industry executive leader, Mr. Paul G. Howes in the USA. In the coming years, Dr. Qiu is hoping to continue to build upon Ophthalmic Therapeutic Innovation, championing for leveraging big data evidence to solve problems and create values for patients and shareholders in revolutionizing modern medicine development.
About Marquis Who's Who®
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® now publishes many Who's Who titles, including Who's Who in America®, Who's Who in the World®, Who's Who in American Law®, Who's Who in Medicine and Healthcare®, Who's Who in Science and Engineering®, and Who's Who in Asia®. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #